Browse All

Current Filters

CLEAR FILTER x

TITLE

Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial

Author:Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   de Sèze, Jérôme   Levy, Michael   Nakashima, Ichiro   Oreja Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Mashhoon, Yasmin   Yountz, Marcus   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.002  

Author Institution:Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, Camperdown, Australia  Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Aurora, CO, USA, Aurora, CO  Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France, Strasbourg, France  Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan  Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos, IdISCC, Madrid, Spain  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK, Oxford, United Kingdom  Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany  Department of Human Neuroscience, University Sapienza, Rome, Italy, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Watertown, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA *At the time this research was conducted., Needham, MA  Department of Neurology, National Cancer Center, Goyang, South Korea, Goyang, Korea, Republic of  

Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Author:Levy, Michael   Pittock, Sean   Barnett, Michael   Bennett, Jeffrey   Berthele, Achim   De Seze, Jerome   Nakashima, Ichiro   Oreja Guevara, Celia   Palace, Jacqueline   Paul, Friedemann   Pozzilli, Carlo   Allen, Kerstin   Mashhoon, Yasmin   Yountz, Marcus   Kim, Ho Jin   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.003  

Author Institution:Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA  Department of Neurology, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA, Rochester, MN  Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia  Department of Neurology, Royal Prince Alfred Hospital, Sydney, NSW, Australia, Camperdown, Australia  Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado, Aurora, CO, USA, Aurora, CO  Department of Neurology, School of Medicine, Technical University of Munich, Munich, Germany, Muenchen, Germany  Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, France, Strasbourg, France  Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan  Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, Sendai, Japan  Department of Neurology, Hospital Clínico Universitario San Carlos, IdISCC, Madrid, Spain  Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain  Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK, Oxford, United Kingdom  Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany  Department of Human Neuroscience, University Sapienza, Rome, Italy, Rome, Italy  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Boston, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA, Watertown, MA  Alexion, AstraZeneca Rare Disease, Boston, MA, USA *At the time this research was conducted., Needham, MA  Department of Neurology, National Cancer Center, Goyang, South Korea, Goyang, Korea, Republic of  

Association of B cell Subsets and Aquaporin-4 antibody titers with Disease Activity in Participants in the N-MOmentum trial Receiving Inebilizumab Treatment

Author:Pittock, Sean   Paul, Friedemann   Kim, Ho Jin   Smith, Michael   Rees, William   Patterson, Kristina   Cree, Bruce   Bennett, Jeffrey   

Session Name:S5: Autoimmune Neurology: NMOSD and MG, A Focus on Treatment Trials  

Topic:Autoimmune Neurology  

Program Number:S5.005  

Author Institution:Mayo Clinic Dept of Neuro, Rochester, MN  Charite Universitatsmedizin in Berlin, Berlin, Germany  National Cancer Center, Goyang, Korea, Republic of  Horizon Therapeutics plc, Gaithersburg, MD  Horizon Therapeutics plc, Deerfield, IL  UCSF, Multiple Sclerosis Center, San Francisco, CA  University of Colorado School of Medicine, Aurora, CO  

Upregulated complement receptors correlate with Fc gamma receptor 3A-positive natural killer cells (NK) and natural killer-T cells (NKT) in neuromyelitis optica spectrum disorder.

Author:Nishiyama, Shuhei   Wright, Amy   Lotan, Itay   Paul, Friedemann   Levy, Michael   

Session Name:S50: Autoimmune Neurology: NMOSD  

Topic:Autoimmune Neurology  

Program Number:S50.003  

Author Institution:Massachusetts General Hospital/Harvard Medical School, Boston, MA  Massachusetts General Hospital, Charlestown, MA  Charite Universitatsmedizin in Berlin, Berlin, Germany  

Identification of multiple sclerosis endophenotypes by high dimensional blood signatures associated with distinct disease trajectories

Author:Gross, Catharina C   Schulte-Mecklenbeck, Andreas   Steinberg, Olga V   Wirth, Timo   Lauks, Sarah   Baranzini, Sergio E   Bittner, Stefan   Bellmann-Strobl, Judith   Bünger, Nora   Eilers, Eva   Eveslage, Maria   Fleischer, Vinzenz   Gisevius, Barbara   Groppa, Sergiu   Haas, Jürgen   Kerschensteiner, Martin   Kirstein, Lucienne   Korsukewitz, Catharina   Lohmann, Lisa   Lünemann, Jan   Lüssi, Felix   Meyer zu Hörste, Gerd   Motte, Jeremias   Ruck, Tobias   Schwab, Nicholas   Meuth, Sven G   Paul, Friedemann   Wildemann, Brigitte   Kümpfel, Tania   Gold, Ralf   Zipp, Frauke   Klotz, Luisa   Wiendl, Heinz   

Session Name:P1: MS Biomarkers  

Topic:MS and Inflammatory Disease  

Program Number:P1.008  

Author Institution:University Hospital Münster, Münster, Germany  University of California San Francisco, San Francisco, CA  University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany  Max Delbrueck Center for Molecular Medicine and Charité Universitätsmedizin Berlin, Berlin, Germany  University of Münster, Münster, Germany  University Hospital Bochum, Bochum, Germany  University of Heidelberg, Heidelberg, Germany  Ludwig Maximilians University of Munich, Munich, Germany  University and University Hospital of Münster, Münster, Germany  Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany  Charite Universitatsmedizin in Berlin, Berlin, Germany  University Hospital Heidelberg, Heidelberg, Germany